References
- Wallace DJ. The evolution of drug discovery in systemic lupus erythematosus. Nat Rev Rheumatol. 2015;11(10):616–620. doi:10.1038/nrrheum.2015.86.
- Rodriguez-Pintó I, Espinosa G, Cervera R. Updating the clinical evidence on belimumab role modulating B-cell response and treatment of systemic lupus erythematosus. Clin Investig. 2015;5(6):561–571. doi:10.4155/cli.15.16.
- Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi:10.1002/art.30613.
- Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215–1226. doi:10.1002/art.34359.
- Furie R, Nicholls K, Cheng -T-T, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014;66(2):379–389. doi:10.1002/art.v66.2.
- Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–1178. doi:10.1002/art.24699.
- Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721–731. doi:10.1016/S0140-6736(10)61354-2.
- Yuen SY, Pope JE. Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford). 2008;47(9):1367–1372. doi:10.1093/rheumatology/ken230.
- Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore). 1993;72(2):113–124. doi:10.1097/00005792-199303000-00005.
- Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299–308.
- Petri M, Kasitanon N, Lee -S-S, et al. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 2008;58(6):1784–1788. doi:10.1002/art.23794.
- Sinclair A, Appel G, Dooley MA, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007;16(12):972–980. doi:10.1177/0961203307084712.
- Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305–1313. doi:10.1002/art.39026.
- Furie R, Toder K, Zapantis E. Lessons learned from the clinical trials of novel biologics and small molecules in lupus nephritis. Semin Nephrol. 2015;35(5):509–520. doi:10.1016/j.semnephrol.2015.08.012.
- Jónsdóttir T, Zickert A, Sundelin B, et al. Long-term follow-up in lupus nephritis patients treated with rituximab–clinical and histopathological response. Rheumatology (Oxford). 2013;52(5):847–855. doi:10.1093/rheumatology/kes348.
- Lew RA, Liang MH, Doros G. Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier. Arthritis Res Ther. 2015;17:345. doi:10.1186/s13075-015-0874-0.